Tris Pharma

77 articles with Tris Pharma

• Tris Pharma Strengthens Its Branded Commercial Leadership Team

  9/4/2019

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, announced the addition of two industry veterans to join its growing branded business

• Tris Pharma Chief Medical Officer Elected to the American Psychiatric Association Assembly Executive Committee

  8/14/2019

  Tris Pharma, Inc. ("Tris"), is announcing that its Chief Medical Officer, Barry K. Herman, M.D., M.M.M. has been elected to the American Psychiatric Association (APA) Assembly Executive Committee. 

• Tris Pharma, Inc. Expands Its Voluntary Nationwide Retail Recall of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, Due to Higher Concentration of Ibuprofen

  1/29/2019

  Tris Pharma, Inc. is expanding the scope of its November 2018 recall by adding three (3) additional lots of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, to the retail (pharmacy) level.

• Tris Pharma to Present Three Posters Covering Data on Dyanavel® XR and Tris' LiquiXR® Technology at the 2019 APSARD Annual Meeting

  1/17/2019

  Tris Pharma, Inc., announced that it will present information on its proprietary drug delivery platform LiquiXR® as well as data from two clinical studies on DYANAVEL XR (amphetamine) extended-release oral suspension, CII, at the 2019 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting held in Washington, D.C., January 18 to January 20, 2019.

• Tris Pharma Presents Clinical Data for DYANAVEL® XR (amphetamine) at the 2018 Neuroscience Education Institute (NEI) Congress

  11/12/2018

  The trial of children 6 to 12 years with ADHD demonstrated that DYANAVEL XR was effective in reducing symptoms of ADHD at 4 hours with a clinical onset at 1 hour and a duration of effect up to 13 hours after dosing

• Tris Pharma Presents Results from Two Clinical Studies on Dyanavel® XR at the Largest Annual Meeting of Child and Adolescent Psychiatrists

  10/24/2018

  65th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) taking place in Seattle, Washington, October 22 to 27, 2018.

• Tris Pharma Announces Hiring of Chief Commercial Officer

  10/10/2018

  Tris Pharma, Inc. today announced the appointment of Thomas Curatolo as Chief Commercial Officer to lead Tris' expanded Attention Deficit Hyperactivity Disorder (ADHD) portfolio.

• Tris Pharma Announces Hiring of New Vice President of Quality & Compliance

  8/27/2018

  Tris Pharma, Inc. today announced the joining of Jeffery Palmer as its new Vice President and Head of Quality & Compliance.

• Tris Pharma, Inc. Appoints New Chief Commercial Officer For Brand Business

  3/10/2017

• Tris Pharma, Inc.’s Results From A Laboratory Classroom Study Of DYANAVEL XR In Children With ADHD Featured At APSARD

  2/9/2017

• Tris Pharma, Inc. Release: FDA Accepts CCP-08 NDA For Full Review

  12/21/2016

• Tris Pharma, Inc. Announces The Launch Of DYANAVEL XR (Amphetamine) Extended-Release Oral Suspension, CII For The Treatment Of Children With ADHD

  4/19/2016

• Tris Pharma, Inc. Announces Appointment Of Chief Commercial Officer Of Its New Brand Business

  4/7/2016

• Tris Pharma, Inc. Announces First Ever FDA-Approved Extended-Release Chewable Tablet

  12/16/2015

• Tris Pharma, Inc. Receives FDA Approval Of Dyanavel XR (amphetamine) CII As Once-Daily Liquid For Treatment Of ADHD In Children

  10/20/2015

• Tris Pharma, Inc. Launches Generic Tussionex As Par's Rights Expire

  10/1/2015

• Tris Pharma, Inc. And Pfizer Consumer Healthcare Enter Into Agreement To Commercialize 12-Hour Extended Release Dextromethorphan Cough Syrup Under The Robitussin Brand

  6/29/2015

• Tris Pharma, Inc. Announces The FDA Acceptance Of NDA For Dyanavel XR

  5/21/2015

• Vernalis PLC And Tris Pharma, Inc. Receive FDA Approval Of NDA For Tuzistra XR (Codeine Polistirex And Chlorpheniramine Polistirex)

  5/1/2015

• Tris Pharma, Inc. Selected As An Award Winner In The New Jersey Business & Industry Association's 2014 Awards For Excellence

  8/27/2014